Why Acadia Pharmaceuticals Inc.’s (ACAD) Stock Is Up 6.82%
As of Tuesday, November 10, Acadia Pharmaceuticals Inc.’s ACAD share price has surged by 6.82%, which has investors questioning if this is right time to sell.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Tudor Pop
Jenna Brashear
Jenna Brashear
Jenna Brashear
| Share Statistics | ACAD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,081.5 | $213.9 | 61% |
|
| Shares Out (Mil) | 175.5 | 55.4 | 73% |
|
| Institutional Ownership | 99.6% | 93.3% | 90% |
|
| Float (Mil) | 129.3 | 40.6 | 65% |
|
| Beta | 0.89 | 0.98 | 52% |
|
| Avg Daily Volume (000s) | 3,796 | 597 | 89% |
|
| Price Change (52-week) |
(25.7%) | 40.9% | 32% |
|
| Growth | ACAD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.4% | 13.2% | 80% |
|
| Net Income (5yr) | 27.6% | (10.7%) | 83% |
|
| EPS (5yr) | 26.9% | 15.5% | 78 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (24.4%) | (15.7%) | 27% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 14 | 13 | 14 | |
| Current EPS | $0.263 | $0.770 | $1.086 | |
| Month Ago EPS | $0.210 | $0.595 | $0.921 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $0.215 | $0.599 | $0.889 | |
| Year/Year Chg | (15.2%) | (66.5%) | (23.3%) | |
| Financials | ACAD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,202 | $39 | 52% |
|
| Net Income (TTM) (Mil) | $362 | ($44) | 74% |
|
| EPS (TTM) | $2.116 | ($1.400) | 72% |
|
| Operating Cash Flow (TTM) (Mil) | $98 | ($34) | 51% |
|
| Net Cash Flow (TTM) (Mil) | $63 | $-0 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $57 | $4 | 40% |
|
| Enterprise Value (Q1) (Mil) | $2,765 | $135 | 53% |
|
| Valuation | ACAD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.22 | 1.97 | 60% |
|
| P/E | 8.5 | 17.6 | 13% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.3 | 0.8 | 15% |
|
| Ratios | ACAD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 63.9% | 67.9% | 76% |
|
| Net Margin | 30.1% | (50.8%) | 88% |
|
| ROA | 23.2% | (47.5%) | 97% |
|
| ROE | 31.4% | (51.9%) | 88% |
|
| Liabilities to Assets | 22.7% | 29.7% | 15% |
|
| F-Score | 6 | 3 | 67% |
|
Passing Stock Screens
As of 11/18/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 21.3% |
| +/- S&P 500: | +13.9 |
| Performance Since Inception: | 22.2% |
| +/- S&P 500: | +14.8 |
| Performance Since Inception: | 13.1% |
| +/- S&P 500: | +5.7 |
| Performance Since Inception: | 12.5% |
| +/- S&P 500: | +5.1 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors